---
title: "Ulixacaltamide in Essential tremor: Product information and disease description"
description: "Formulary evidence on Ulixacaltamide in Essential tremor: Product information and disease description. Covers Product description and Place of product in therapy. 64 evidence topics quoted from 60 sources."
canonical: "https://www.evicenter.com/drugs/ulixacaltamide--essential-tremor/product-information-and-disease-description"
published: "2026-09-14T15:39:06-04:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Ulixacaltamide in Essential tremor: Product information and disease description

<a id="product-information-and-disease-description"></a>

## 2 Product Information and Disease Description

<a id="heading-2.1"></a>

### 2.1 Product Description

<a id="heading-2.1.1"></a>

#### 2.1.1 Phase of Product Development

<a id="topic-2.1.1-1"></a>

##### Breakthrough Therapy Designation

| Type of information | Source quotation |
| --- | --- |
| Special FDA designation: date | “December 29, 2025” |
| Special FDA designation | “Breakthrough Therapy Designation for Ulixacaltamide HCl in Essential Tremor” |

Source: [Praxis Precision Medicines Breakthrough Therapy Designation announcement (2025)](https://ir.praxismedicines.com/news-releases/news-release-details/praxis-precision-medicines-announces-fda-has-granted/)

<a id="topic-2.1.1-2"></a>

##### Regulatory status: Under review; NDA submitted by February 2026, with a target action date of January 2027

> “November 9, 2026”
> “The New Drug Application (NDA) for ulixacaltamide remains under FDA review, with a Prescription Drug User Fee Act (PDUFA) target action date of January 29, 2027.”

Source: [Praxis Precision Medicines third quarter 2026 results announcement (2026)](https://ir.praxismedicines.com/news-releases/news-release-details/praxis-precision-medicines-provides-corporate-update-and-21)

> “February 19, 2026”
> “Praxis has submitted an NDA for the treatment of ET.”

Source: [Praxis Precision Medicines fourth quarter and full-year 2025 results announcement (2026)](https://investors.praxismedicines.com/news-releases/news-release-details/praxis-precision-medicines-provides-corporate-update-and-18)

<a id="topic-2.1.1-3"></a>

##### FDA target action date

> “PDUFA target action date of January 29, 2027”

Source: [Praxis Precision Medicines NDA acceptance announcement (2026)](https://ir.praxismedicines.com/news-releases/news-release-details/praxis-precision-medicines-announces-fda-acceptance-new-drug)

<a id="topic-2.1.1-4"></a>

##### Regulatory review and FDA Advisory Committee meeting

> “August 6, 2026”
> “FDA identified no major safety or efficacy concerns to date.”
> “The agency confirmed that no advisory committee meeting is planned.”

Source: [Praxis Precision Medicines second quarter 2026 results announcement (2026)](https://ir.praxismedicines.com/news-releases/news-release-details/praxis-precision-medicines-provides-corporate-update-and-20)

<a id="topic-2.1.1-5"></a>

##### Investigational status

> “Ulixacaltamide is investigational and has not been approved by the FDA.”

Source: [Praxis Precision Medicines AAN 2026 Annual Meeting page (2026)](https://praxismedicines.com/2026-aan-annual-meeting/)

<a id="topic-2.1.1-6"></a>

##### Launch

No evidence found.

<a id="topic-2.1.1-7"></a>

##### Approval dates in other countries

No evidence found.

<a id="heading-2.1.2"></a>

#### 2.1.2 Product Information

<a id="heading-2.1.2.1"></a>

##### 2.1.2.1 Generic, Brand Name and Therapeutic Class of Product

<a id="topic-2.1.2.1-1"></a>

###### Manufacturer and investigational product name

| Type of information | Source quotation |
| --- | --- |
| Manufacturer name | “Praxis Precision Medicines” |
| Unapproved product name | “Ulixacaltamide HCl” |

Source: [Praxis Precision Medicines Breakthrough Therapy Designation announcement (2025)](https://ir.praxismedicines.com/news-releases/news-release-details/praxis-precision-medicines-announces-fda-has-granted/)

<a id="topic-2.1.2.1-2"></a>

###### Manufacturer: Praxis Precision Medicines

> “The FDA has accepted Praxis’ NDA for ulixacaltamide for the treatment of ET”

Source: [Praxis Precision Medicines first quarter 2026 results announcement (2026)](https://ir.praxismedicines.com/news-releases/news-release-details/praxis-precision-medicines-provides-corporate-update-and-19)

<a id="topic-2.1.2.1-3"></a>

###### Therapeutic class

> “PRAX-944 is an orally active, small molecule that belongs to the class of T-type Ca2+-channel blockers.”

Source: [ClinicalTrials.gov NCT05021978](https://cdn.clinicaltrials.gov/large-docs/78/NCT05021978/Prot_000.pdf)

<a id="topic-2.1.2.1-4"></a>

###### Confirmed commercial brand name

No evidence found.

<a id="heading-2.1.2.2"></a>

##### 2.1.2.2 Dosage Forms and Strengths

<a id="topic-2.1.2.2-1"></a>

###### Investigational formulation in PRAX-944-221

| Attribute | Quoted protocol information |
| --- | --- |
| Dosage form | “Modified-release tablet” |
| Unit strength | “20 mg” |
| Route | “Oral” |

Source: [ClinicalTrials.gov NCT05021978](https://cdn.clinicaltrials.gov/large-docs/78/NCT05021978/Prot_000.pdf)

<a id="topic-2.1.2.2-2"></a>

###### Transdermal formulation development

> “A strategic collaboration was initiated in July 2026 with Remagine Labs to develop a transdermal patch of ulixacaltamide for ET.”

Source: [Praxis Precision Medicines second quarter 2026 results announcement (2026)](https://ir.praxismedicines.com/news-releases/news-release-details/praxis-precision-medicines-provides-corporate-update-and-20)

<a id="topic-2.1.2.2-3"></a>

###### Commercial dosage forms and strengths

No evidence found.

<a id="topic-2.1.2.2-4"></a>

###### Material safety data sheet

No evidence found.

<a id="heading-2.1.2.3"></a>

##### 2.1.2.3 Average Sales Price and Wholesale Acquisition Cost

<a id="topic-2.1.2.3-1"></a>

###### Manufacturer pricing discussion without a disclosed final price

> “We talked about a little bit over maybe $50,000 to $100,000 per year.”
> “we're not going to disclose the price specifically”

Source: [Praxis Precision Medicines earnings call transcript (2026)](https://www.fool.com/earnings/call-transcripts/2026/08/13/praxis-prax-q2-2026-earnings-call-transcript/)

<a id="topic-2.1.2.3-2"></a>

###### Marketed-product average sales price and wholesale acquisition cost

Not applicable.

<a id="heading-2.1.2.4"></a>

##### 2.1.2.4 American Hospital Formulary Service (AHFS), or Other Drug Classification

<a id="topic-2.1.2.4-1"></a>

###### Pharmacologic classification

> “PRAX-944 is an orally active, small molecule that belongs to the class of T-type Ca2+-channel blockers.”

Source: [ClinicalTrials.gov NCT05021978](https://cdn.clinicaltrials.gov/large-docs/78/NCT05021978/Prot_000.pdf)

<a id="topic-2.1.2.4-2"></a>

###### AHFS classification code

No evidence found.

<a id="heading-2.1.2.5"></a>

##### 2.1.2.5 Indication

<a id="topic-2.1.2.5-1"></a>

###### Investigational indication

| Type of information | Source quotation |
| --- | --- |
| Disease or anticipated indication | “Essential Tremor” |

Source: [Praxis Precision Medicines Breakthrough Therapy Designation announcement (2025)](https://ir.praxismedicines.com/news-releases/news-release-details/praxis-precision-medicines-announces-fda-has-granted/)

<a id="heading-2.1.2.6"></a>

##### 2.1.2.6 Pharmacology

<a id="heading-2.1.2.6.1"></a>

###### 2.1.2.6.1 Mechanism of Action

<a id="topic-2.1.2.6.1-1"></a>

###### Proposed mechanism of action

> “designed to block abnormal neuronal burst firing in the Cerebello-Thalamo-Cortical (CTC) circuit correlated with tremor activity.”

Source: [Praxis Precision Medicines pre-NDA meeting announcement (2025)](https://ir.praxismedicines.com/news-releases/news-release-details/praxis-precision-medicines-announces-positive-pre-nda-meeting)

<a id="topic-2.1.2.6.1-2"></a>

###### Structural pharmacology of Z944 and Cav3.1

> “The arch-shaped Z944 molecule reclines in the central cavity of the pore domain”

Source: [Zhao et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/31766050/)

Additional sources: [Zhao et al. (2024)](https://www.nature.com/articles/s41586-024-07414-z); [Huang et al. (2024)](https://www.nature.com/articles/s41422-024-00959-8)

<a id="heading-2.1.2.6.2"></a>

###### 2.1.2.6.2 Pharmacodynamics

<a id="topic-2.1.2.6.2-1"></a>

###### Human sigma-power biomarker response

> “In healthy participants, sigma-power was similarly reduced by 34% to 50% at 10 to 100 mg, with no further reduction at 120 mg.”

Source: [Scott et al. (2022)](https://movementdisorders.onlinelibrary.wiley.com/doi/10.1002/mds.28969)

<a id="topic-2.1.2.6.2-2"></a>

###### Preclinical absence-seizure model

> “Z941 and Z944 potently suppressed absence seizures by 85 to 90%”

Source: [Tringham et al. (2012)](https://pubmed.ncbi.nlm.nih.gov/22344687/)

<a id="topic-2.1.2.6.2-3"></a>

###### Experimental Cav1.4 channel modulation

> “ML218 and Z944 are dual Cav1/Cav3 modulators of CaV1.4”

Source: [Sun et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13080778/)

<a id="heading-2.1.2.6.3"></a>

###### 2.1.2.6.3 Pharmacokinetics

<a id="topic-2.1.2.6.3-1"></a>

###### Steady-state sampling in the healthy-participant study

> “Dose titration allowed for 4 days at each level to achieve steady-state plasma concentrations”

Source: [Scott et al. (2022)](https://movementdisorders.onlinelibrary.wiley.com/doi/10.1002/mds.28969)

<a id="topic-2.1.2.6.3-2"></a>

###### Numerical absorption, distribution, metabolism, and elimination parameters

No evidence found.

<a id="heading-2.1.2.7"></a>

##### 2.1.2.7 Contraindications/Warnings/Precautions/Adverse Effects

<a id="heading-2.1.2.7.1"></a>

###### 2.1.2.7.1 Warnings and Precautions

Not applicable.

<a id="heading-2.1.2.8"></a>

##### 2.1.2.8 Special Populations

<a id="topic-2.1.2.8-1"></a>

###### Adult age range in the original Essential3 eligibility criteria

> “age of 18 and 85 years (inclusive)”

Source: [Able et al. (2024b)](https://praxismedicines.com/wp-content/uploads/2024/09/MDS2024_E3_StudyDesign_Poster_QRcode.pdf)

<a id="topic-2.1.2.8-2"></a>

###### Pediatric use, pregnancy, lactation, and renal or hepatic impairment

No evidence found.

<a id="heading-2.1.2.9"></a>

##### 2.1.2.9 Drug/Drug, Drug/disease Interactions

<a id="heading-2.1.2.9.1"></a>

###### 2.1.2.9.1 Effects of Other Drugs on Ulixacaltamide

No evidence found.

<a id="heading-2.1.2.9.2"></a>

###### 2.1.2.9.2 Effects of Ulixacaltamide on Other Drugs

No evidence found.

<a id="heading-2.1.2.10"></a>

##### 2.1.2.10 Dosing and Administration

<a id="heading-2.1.2.10.1"></a>

###### 2.1.2.10.1 Dosage

<a id="topic-2.1.2.10.1-1"></a>

###### Essential3 investigational regimen

> “ulixacaltamide hydrochloride 60mg QD (after 2-week titration)”

Source: [Farmer et al. (2026a)](https://index.mirasmart.com/AAN2026/PDFfiles/AAN2026-005412.html)

Additional sources: [ClinicalTrials.gov NCT06087276](https://clinicaltrials.gov/study/NCT06087276)

<a id="heading-2.1.2.10.2"></a>

###### 2.1.2.10.2 Administration

<a id="topic-2.1.2.10.2-1"></a>

###### Oral administration and food

> “Formulated as a once-daily oral medicine that can be taken any time of day, with or without food”

Source: [Able (2024a)](https://praxismedicines.com/wp-content/uploads/2024/04/AAN2024_Propranolol_Talk_QRcode.pdf)

<a id="heading-2.1.2.11"></a>

##### 2.1.2.11 Access and Distribution

<a id="topic-2.1.2.11-1"></a>

###### Anticipated distribution strategy

> “May 7, 2026”
> “Distribution network is established, with commercial inventory build in-progress ahead of launch.”

Source: [Praxis Precision Medicines first quarter 2026 results announcement (2026)](https://ir.praxismedicines.com/news-releases/news-release-details/praxis-precision-medicines-provides-corporate-update-and-19)

<a id="topic-2.1.2.11-2"></a>

###### Expanded access policy

> “Requests will be considered on a case-by-case basis.”
> “All requests must be submitted by the patient’s treating physician.”

Source: [Praxis Precision Medicines Expanded Access Policy](https://praxismedicines.com/eap/)

<a id="topic-2.1.2.11-3"></a>

###### Anticipated patient support programs

No evidence found.

<a id="heading-2.1.2.12"></a>

##### 2.1.2.12 Co-prescribed/Concomitant Therapies

<a id="topic-2.1.2.12-1"></a>

###### Stable background propranolol in Essential1

> “a stable dose of propranolol for the duration of the study.”

Source: [Able (2024a)](https://praxismedicines.com/wp-content/uploads/2024/04/AAN2024_Propranolol_Talk_QRcode.pdf)

Additional sources: [Giroux et al. (2024)](https://www.neurology.org/doi/10.1212/WNL.0000000000205217)

<a id="heading-2.1.2.13"></a>

##### 2.1.2.13 Effect of Ulixacaltamide on Quality Measures

No evidence found.

<a id="heading-2.1.2.14"></a>

##### 2.1.2.14 Product comparison

<a id="topic-2.1.2.14-1"></a>

###### Head-to-head comparisons with established essential tremor therapies

No evidence found.

<a id="topic-2.1.2.14-2"></a>

###### Placebo-controlled study of NBI-827104

> “NBI-827104 did not meet the primary or secondary efficacy endpoints.”

Source: [de Cuba et al. (2023)](https://www.mdsabstracts.org/abstract/an-evaluation-of-nbi-827104-for-essential-tremor-results-from-a-randomized-double-blind-placebo-controlled-dose-escalation-crossover-study/)

<a id="topic-2.1.2.14-3"></a>

###### Adverse events in the SAGE-324 KINETIC trial

> “somnolence, dizziness, fatigue, and balance disorder.”

Source: [Elble et al. (2024)](https://movementdisorders.onlinelibrary.wiley.com/doi/10.1002/mds.29731)

Additional sources: [Papapetropoulos et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33764619/); [Zhang et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11533039/); [Mukherjee and Pandey (2025)](https://movementdisorders.onlinelibrary.wiley.com/doi/abs/10.1002/mdc3.70147); [AlMojel and Fasano (2026)](https://www.sciencedirect.com/science/article/pii/S1353802026007947)

<a id="heading-2.2"></a>

### 2.2 Place of Product in Therapy

<a id="heading-2.2.1"></a>

#### 2.2.1 Disease Description

<a id="heading-2.2.1.1"></a>

##### 2.2.1.1 Definition and Etiology

<a id="topic-2.2.1.1-1"></a>

###### Sporadic disease and familial susceptibility

> “ET is often sporadic”
> “first-degree relatives of patients with ET are 5 times more likely to develop ET compared to the general population”

Source: [Pahwa et al. (2024)](https://tremorjournal.org/articles/10.5334/tohm.973)

<a id="heading-2.2.1.2"></a>

##### 2.2.1.2 Epidemiology

<a id="heading-2.2.1.2.1"></a>

###### 2.2.1.2.1 Incidence of Essential tremor

<a id="topic-2.2.1.2.1-1"></a>

###### Annual incidence in Rochester, Minnesota, 1935-79

> “Rochester, Minnesota”
> “1935-79”
> “Age adjusted annual incidence rate was not different in males (18.3/100 000) and females (17.1/100 000).”

Source: [Rajput et al. (1984)](https://pmc.ncbi.nlm.nih.gov/articles/PMC1027820/)

<a id="heading-2.2.1.2.2"></a>

###### 2.2.1.2.2 Prevalence of Essential tremor

<a id="topic-2.2.1.2.2-1"></a>

###### Estimated US prevalence including undiagnosed disease

> “ET cases (2012) ranged from 6.38 to 7.63 million (mean = 7.01 million).”
> “This corresponds to approximately 2.2% of the US population.”

Source: [Louis and Ottman (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4137360/)

<a id="topic-2.2.1.2.2-2"></a>

###### Prevalence of diagnosed disease

> “After standardization, prevalence was 0.42%; in 2024, 1.1 million US adults were estimated to have diagnosed ET.”

Source: [Lin et al. (2025)](https://tremorjournal.org/articles/10.5334/tohm.1060)

<a id="topic-2.2.1.2.2-3"></a>

###### Prevalence by ascertainment strategy in northeast-central Pennsylvania

| Ascertainment strategy | Crude prevalence | Age-standardized prevalence |
| --- | --- | --- |
| Neurology cohort | “0.261% (95% CI, 0.252–0.271)” | “0.40% (95% CI, 0.39–0.41)” |
| All-specialties cohort | “0.653% (95% CI, 0.638–0.668)” | “1.01% (95% CI, 1.00–1.02)” |

Source: [Kratovil et al. (2026)](https://tremorjournal.org/articles/10.5334/tohm.1229)

Additional sources: [Song et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8035980/)

<a id="heading-2.2.1.3"></a>

##### 2.2.1.3 Natural History, Survival, and Mortality

<a id="topic-2.2.1.3-1"></a>

###### Historical population-based survival comparison

> “Survival after diagnosis of essential tremor is comparable to age and sex matched population of West North Central United States.”

Source: [Rajput et al. (1984)](https://pmc.ncbi.nlm.nih.gov/articles/PMC1027820/)

Additional sources: [Okelberry et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38538475/)

<a id="heading-2.2.1.4"></a>

##### 2.2.1.4 Pathophysiology

<a id="topic-2.2.1.4-1"></a>

###### T-type calcium channels and aberrant neuronal burst firing in essential tremor and Parkinson’s disease

> “T-type calcium channels play a key role in regulating this activity in both the disorders.”

Source: [Matthews et al. (2023)](https://onlinelibrary.wiley.com/doi/epdf/10.1002/acn3.51735)

<a id="heading-2.2.1.5"></a>

##### 2.2.1.5 Diagnosis

<a id="topic-2.2.1.5-1"></a>

###### Functional assessment in the current clinical advisory

> “History should be taken to understand how tremor impacts daily living and function, to determine if treatment is indicated.”

Source: [International Essential Tremor Foundation (2025)](https://www.guidelinecentral.com/guideline/502775/pocket-guide/502776/)

Additional sources: [Bhatia et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6530552/)

<a id="heading-2.2.1.6"></a>

##### 2.2.1.6 Clinical Presentation - Signs and Symptoms

<a id="topic-2.2.1.6-1"></a>

###### Motor symptoms: upper limb tremor and additional affected regions

> “ET is characterized by involuntary rhythmic movement in the upper limbs”
> “head, vocal cords, or legs.”

Source: [Praxis Precision Medicines Essential1 randomized withdrawal results announcement (2023)](https://investors.praxismedicines.com/news-releases/news-release-details/praxis-precision-medicines-announces-positive-data-randomized)

<a id="topic-2.2.1.6-2"></a>

###### Nonmotor symptoms: cognition, mood, balance, and sleep

> “poorer balance, cognitive impairment, depression and sleep dysregulation.”

Source: [Kellner et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5739080/)

<a id="heading-2.2.1.7"></a>

##### 2.2.1.7 Long-term Morbidity

<a id="topic-2.2.1.7-1"></a>

###### Burden beyond tremor

> “increased risk of falls, depression, anxiety, poor sleep quality”

Source: [Gerbasi et al. (2022)](https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2022.891446/full)

<a id="heading-2.2.1.8"></a>

##### 2.2.1.8 Burden of Essential tremor

<a id="heading-2.2.1.8.1"></a>

###### 2.2.1.8.1 Humanistic Burden and Health-related Quality of Life

<a id="topic-2.2.1.8.1-1"></a>

###### Work and activity impairment

> “Work impairment is significantly correlated with tremor severity.”

Source: [Gerbasi et al. (2025a)](https://tremorjournal.org/articles/10.5334/tohm.1034)

<a id="topic-2.2.1.8.1-2"></a>

###### Disease-specific quality-of-life instrument validation

> “Preliminary validity data are encouraging.”

Source: [Tröster et al. (2005)](https://pubmed.ncbi.nlm.nih.gov/16103000/)

Additional sources: [Gerbasi et al. (2024)](https://tremorjournal.org/articles/10.5334/tohm.877)

<a id="heading-2.2.1.8.2"></a>

###### 2.2.1.8.2 Economic Burden and Healthcare Resource Utilization

<a id="topic-2.2.1.8.2-1"></a>

###### All-cause and essential tremor-related healthcare costs in 2019 US dollars

> “The average all-cause HCC was $17 560 per ET patient per year (PPPY)”
> “ET-related HCC accounting for 13% ($2233 PPPY)”

Source: [Dai et al. (2022)](https://jheor.org/article/37307-multiple-comorbidities-psychiatric-disorders-healthcare-resource-utilization-and-costs-among-adults-with-essential-tremor-a-retrospective-observati)

<a id="topic-2.2.1.8.2-2"></a>

###### Direct medical costs in 2018-2019

> “ET patients aged 40+ had about USD 28,217 in direct medical costs per year”
> “USD 1,601 more than matched comparisons (p < 0.001)”

Source: [Kapinos and Louis (2025)](https://pubmed.ncbi.nlm.nih.gov/39396507/)

Additional sources: [Kapinos and Louis (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9969906/)

<a id="heading-2.2.1.8.3"></a>

###### 2.2.1.8.3 Economic Impact of Essential tremor on Families

<a id="topic-2.2.1.8.3-1"></a>

###### Care partner prevalence and weekly caregiving time

> “Approximately 25% of patients in this clinic-based cohort required care partners, with average caregiving time ranging from 24 to 44 hours per week.”

Source: [Gerbasi et al. (2025b)](https://tremorjournal.org/articles/10.5334/tohm.1046)

<a id="topic-2.2.1.8.3-2"></a>

###### Unpaid caregiving excluded from medical-cost estimates

> “Unpaid work of this type has not been included in economic estimates of medical costs associated with ET”

Source: [Gerbasi et al. (2025b)](https://tremorjournal.org/articles/10.5334/tohm.1046)

<a id="topic-2.2.1.8.3-3"></a>

###### Activities supported by informal caregivers

> “Caregivers most commonly provided assistance with writing and cooking.”

Source: [Morgan et al. (2017)](https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2017.00396/full)

Additional sources: [Kellner et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5739080/)

<a id="heading-2.2.1.8.4"></a>

###### 2.2.1.8.4 Economic Impact of Diagnostic Testing

Not applicable.

<a id="heading-2.2.2"></a>

#### 2.2.2 Approaches to Treatment

<a id="heading-2.2.2.1"></a>

##### 2.2.2.1 Current Treatment Options and Standard of Care

<a id="heading-2.2.2.1.1"></a>

###### 2.2.2.1.1 Beta-Adrenergic Blockers

<a id="topic-2.2.2.1.1-1"></a>

###### Established first-line pharmacologic recommendations

> “propranolol, primidone (Level A, established as effective)”

Source: [Zesiewicz et al. (2011)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3208950/)

<a id="heading-2.2.2.1.2"></a>

###### 2.2.2.1.2 Antiseizure Medications

<a id="topic-2.2.2.1.2-1"></a>

###### Primidone in the MDS evidence-based review

> “Propranolol and primidone”
> “clinically useful”

Source: [Ferreira et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/31046186/)

<a id="topic-2.2.2.1.2-2"></a>

###### Topiramate dose qualification in the MDS review

> “Propranolol and primidone were classified as clinically useful, similar to Topiramate, but only for doses higher than 200 mg/day.”

Source: [Ferreira et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/31046186/)

<a id="heading-2.2.2.1.3"></a>

###### 2.2.2.1.3 Benzodiazepines

<a id="topic-2.2.2.1.3-1"></a>

###### Second-line pharmacologic recommendations including alprazolam

> “alprazolam, atenolol, gabapentin (monotherapy), sotalol, topiramate (Level B, probably effective)”

Source: [Zesiewicz et al. (2011)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3208950/)

<a id="heading-2.2.2.1.4"></a>

###### 2.2.2.1.4 Botulinum Toxin Injections

<a id="topic-2.2.2.1.4-1"></a>

###### Recommendations for refractory essential tremor

> “Botulinum toxin type A and thalamic deep-brain stimulation are recommended for refractory ET.”

Source: [Zappia et al. (2013)](https://pubmed.ncbi.nlm.nih.gov/22886006/)

<a id="heading-2.2.2.1.5"></a>

###### 2.2.2.1.5 Deep Brain Stimulation

<a id="topic-2.2.2.1.5-1"></a>

###### MDS recommendations for thalamic interventions

> “Unilateral Ventralis intermedius thalamic DBS, radiofrequency thalamotomy, and MRI-guided focused ultrasound thalamotomy were considered possibly useful.”

Source: [Ferreira et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/31046186/)

<a id="heading-2.2.2.1.6"></a>

###### 2.2.2.1.6 Ablative Thalamic Procedures

<a id="topic-2.2.2.1.6-1"></a>

###### Radiofrequency and MRI-guided focused ultrasound thalamotomy

> “Unilateral Ventralis intermedius thalamic DBS, radiofrequency thalamotomy, and MRI-guided focused ultrasound thalamotomy were considered possibly useful.”

Source: [Ferreira et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/31046186/)

Additional sources: [Health Quality Ontario (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5963668/)

<a id="heading-2.2.2.1.7"></a>

###### 2.2.2.1.7 Peripheral Nerve Stimulation

<a id="topic-2.2.2.1.7-1"></a>

###### Randomized trial of transcutaneous peripheral nerve stimulation

| Outcome | Active stimulation | Sham stimulation |
| --- | --- | --- |
| Randomized participants | “83” | “42” |
| mADL reduction at 90 days | “6.9 points” | “2.7 points” |
| Skin irritation | “28 of 83 participants (33.7%)” | “2 of 42 (4.8%)” |

Source: [Ondo et al. (2025)](https://jamanetwork.com/journals/jamaneurology/article-abstract/2840156)

<a id="heading-2.2.2.1.8"></a>

###### 2.2.2.1.8 Adaptive Equipment and Occupational Strategies

<a id="topic-2.2.2.1.8-1"></a>

###### Assistive devices in the current clinical advisory

> “Assistive devices can enhance participation in meaningful activities and well-being.”

Source: [International Essential Tremor Foundation (2025)](https://www.guidelinecentral.com/guideline/502775/pocket-guide/502776/)

<a id="heading-2.2.2.1.9"></a>

###### 2.2.2.1.9 Limitations of Current Therapies

<a id="topic-2.2.2.1.9-1"></a>

###### Summary

At two years, reported treatment discontinuation was 40% for propranolol and 47% for primidone. A 2024 survey included 411 participants with essential tremor and 152 neurologists; up to 77% of surveyed participants reported that symptoms were not manageable with current treatments. Approximately half of participants in a separate claims-based essential tremor population received no pharmacotherapy during follow-up. The 2026 MDS review reported insufficient evidence for a confident efficacy recommendation under its review criteria. That finding concerns the certainty of the included evidence, rather than demonstrating that every intervention is ineffective.

Source: [Vetterick et al. (2022)](https://link.springer.com/content/pdf/10.1007/s12325-022-02318-8.pdf?pdf=button); [Able et al. (2025a)](https://praxismedicines.com/wp-content/uploads/2025/04/AAN2025_HCPxPatient-Survey_Poster_QRcode.pdf); [Pahwa et al. (2024)](https://tremorjournal.org/articles/10.5334/tohm.973); [Dash et al. (2026)](https://movementdisorders.onlinelibrary.wiley.com/doi/10.1002/mds.70184)

<a id="topic-2.2.2.1.9-2"></a>

###### Discontinuation of current pharmacotherapies

> “By 2 years of treatment, the discontinuation rate was 40% for propranolol, 47% for primidone, and approximately 40% for all treatments”

Source: [Vetterick et al. (2022)](https://link.springer.com/content/pdf/10.1007/s12325-022-02318-8.pdf?pdf=button)

<a id="topic-2.2.2.1.9-3"></a>

###### Evidence gaps identified by the MDS evidence-based review

> “There was insufficient evidence for voice and head tremor as well as for the remaining interventions.”
> “All the above recommendations were made for limb tremor in essential tremor.”
> “There is a need to improve study design in essential tremor and overcome the limitation of small sample sizes, cross-over studies, short-term follow-up studies, and use of nonvalidated clinical scales.”

Source: [Ferreira et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/31046186/)

<a id="topic-2.2.2.1.9-4"></a>

###### Patient and neurologist survey

> “2024”
> “411 patients”
> “152 neurologists”
> “Up to 77% of patients reported not feeling their symptoms are manageable with current treatments.”

Source: [Able et al. (2025a)](https://praxismedicines.com/wp-content/uploads/2025/04/AAN2025_HCPxPatient-Survey_Poster_QRcode.pdf)

<a id="topic-2.2.2.1.9-5"></a>

###### Pharmacotherapy use

> “Within the entire ET study population, approximately half of patients did not receive ET pharmacotherapy during follow-up.”

Source: [Pahwa et al. (2024)](https://tremorjournal.org/articles/10.5334/tohm.973)

<a id="topic-2.2.2.1.9-6"></a>

###### Updated evidence-based review of commercially available interventions

> “commercially available”
> “MEDLINE (1946 to April 2024)”
> “there was insufficient evidence to confidently reach a (likely) efficacious recommendation for any of these interventions”

Source: [Dash et al. (2026)](https://movementdisorders.onlinelibrary.wiley.com/doi/10.1002/mds.70184)

<a id="heading-2.2.2.2"></a>

##### 2.2.2.2 Place in Treatment, Anticipated Use, and Care Setting

<a id="topic-2.2.2.2-1"></a>

###### Summary

Ulixacaltamide is an investigational oral treatment for adults with essential tremor. The phase 3 regimen was 60 mg once daily after titration. Supporting evidence includes treatment alongside stable propranolol, but these data do not establish superiority to propranolol or primidone. The available pivotal studies compare ulixacaltamide with placebo, including withdrawal of treatment in selected responders. Routine use and final prescribing conditions remain dependent on regulatory review. The manufacturer reports an established distribution network; expanded-access requests must come from the treating physician and are considered individually.

Source: [Praxis Precision Medicines AAN 2026 Annual Meeting page (2026)](https://praxismedicines.com/2026-aan-annual-meeting/); [Farmer et al. (2026a)](https://index.mirasmart.com/AAN2026/PDFfiles/AAN2026-005412.html); [Able (2024a)](https://praxismedicines.com/wp-content/uploads/2024/04/AAN2024_Propranolol_Talk_QRcode.pdf); [Brillman et al. (2026a)](https://praxismedicines.com/aan2026-17-002/); [Farmer (2026b)](https://praxismedicines.com/aan2026-pl5-001/); [Praxis Precision Medicines first quarter 2026 results announcement (2026)](https://ir.praxismedicines.com/news-releases/news-release-details/praxis-precision-medicines-provides-corporate-update-and-19); [Praxis Precision Medicines Expanded Access Policy](https://praxismedicines.com/eap/)

<a id="heading-2.2.2.3"></a>

##### 2.2.2.3 Heterogeneity of Treatment Effect

<a id="topic-2.2.2.3-1"></a>

###### Exploratory Essential1 propranolol subgroup: week 8 response with at least 3-point mADL11 improvement

| Background treatment | Ulixacaltamide | Placebo |
| --- | --- | --- |
| Concomitant propranolol | “48%” | “25%” |

Source: [Able (2024a)](https://praxismedicines.com/wp-content/uploads/2024/04/AAN2024_Propranolol_Talk_QRcode.pdf)

Additional sources: [Giroux et al. (2024)](https://www.neurology.org/doi/10.1212/WNL.0000000000205217)

<a id="heading-2.2.2.4"></a>

##### 2.2.2.4 Care Management Intervention Strategies

<a id="topic-2.2.2.4-1"></a>

###### Patient and caregiver psychosocial support

> “address patient embarrassment and perceived embarrassment to better support caregivers and ET patients.”

Source: [Kellner et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5739080/)

<a id="heading-2.2.2.5"></a>

##### 2.2.2.5 Other Product Development or Post-marketing Obligations Required by the FDA

Not applicable.

<a id="heading-2.2.2.6"></a>

##### 2.2.2.6 Ongoing Post-approval Monitoring

Not applicable.

<a id="heading-2.2.2.7"></a>

##### 2.2.2.7 Expected Outcomes of Therapy

<a id="topic-2.2.2.7-1"></a>

###### Daily-function outcome assessed in Essential3 Study 1

> “change from baseline to Day 56 in mADL11”

Source: [Brillman et al. (2026b)](https://www.aan.com/msa/public/events/abstractdetails/63690)

<a id="topic-2.2.2.7-2"></a>

###### Disease modification, prevention of progression, and survival benefit

No evidence found.

## Related pages
- [Ulixacaltamide: Essential tremor](https://www.evicenter.com/drugs/ulixacaltamide--essential-tremor) · [Markdown](https://www.evicenter.com/drugs/ulixacaltamide--essential-tremor.md)
- [Ulixacaltamide in Essential tremor: Terms and abbreviations](https://www.evicenter.com/drugs/ulixacaltamide--essential-tremor/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/ulixacaltamide--essential-tremor/terms-and-abbreviations.md)
- [Ulixacaltamide: Essential tremor](https://www.evicenter.com/drugs/ulixacaltamide--essential-tremor/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ulixacaltamide--essential-tremor/executive-summary.md)
- [Ulixacaltamide in Essential tremor: Clinical evidence](https://www.evicenter.com/drugs/ulixacaltamide--essential-tremor/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/ulixacaltamide--essential-tremor/clinical-evidence.md)
- [Ulixacaltamide in Essential tremor: Economic information and modeling report](https://www.evicenter.com/drugs/ulixacaltamide--essential-tremor/economics) · [Markdown](https://www.evicenter.com/drugs/ulixacaltamide--essential-tremor/economics.md)
- [Ulixacaltamide in Essential tremor: References](https://www.evicenter.com/drugs/ulixacaltamide--essential-tremor/references) · [Markdown](https://www.evicenter.com/drugs/ulixacaltamide--essential-tremor/references.md)
- [Ulixacaltamide in Essential tremor: prevalence by geography](https://www.evicenter.com/drugs/ulixacaltamide--essential-tremor/prevalence) · [Markdown](https://www.evicenter.com/drugs/ulixacaltamide--essential-tremor/prevalence.md)
- [Ulixacaltamide in Essential tremor: cost-effectiveness analyses and utility weights](https://www.evicenter.com/drugs/ulixacaltamide--essential-tremor/cost-effectiveness-analyses) · [Markdown](https://www.evicenter.com/drugs/ulixacaltamide--essential-tremor/cost-effectiveness-analyses.md)
